

Table SI. Summary of select therapeutic approaches and outcomes in pulmonary carcinoid from recent literature.

First author/s, year	Category	Patient/study characteristics	Treatment intervention	Reported efficacy outcome	(Refs.)
Trpezanovski <i>et al</i> , 2025	1. Novel systemic/targeted therapies	13 y/o female, bronchial carcinoid, neoadjuvant setting	Lu-177 DOTATATE (PRRT) multi-cycle, dose-escalated	Significant metabolic response in nodal mets; PR of primary tumor; well-tolerated.	(17)
Cooper <i>et al</i> , 2024		Metastatic Pulmonary Carcinoid, DLL3+, progressed on prior therapies	Tarlatamab (DLL3-targeting BiTE)	Clinical response observed in DLL3-expressing metastatic atypical carcinoid.	(18)
Owen <i>et al</i> , 2023	2. Immunotherapy and combinations	Subgroup of 11 patients with lung NETs	Combination nivolumab and temozolomide	ORR: 64% (7/11) in lung NET subgroup (lung vs. others, P=0.02).	(16)
Hu <i>et al</i> , 2024	3. Other notable management	58 y/o female, mixed atypical carcinoid & adenocarcinoma (ALK+)	Lobectomy + adjuvant chemo (etoposide/carboplatin x4). Recommended second-generation ALK-TKI targeted antitumor therapy, but the patient refused	Surgical resection performed; no tumor recurrence has been observed after 1 year of follow-up.	(19)
Çağan <i>et al</i> , 2025		77 y/o male, metachronous contralateral carcinoid (7 yrs post-lobectomy)	Initial lobectomy, then contralateral recurrence managed	Highlights need for long-term surveillance.	(20)
Aldrete <i>et al</i> , 2024		32 y/o female, severe ectopic ACTH syndrome from Pulmonary Carcinoid	Steroidogenesis inhibitors → cryoablation (palliative)	Patient died 6 months post-diagnosis (aggressive course).	(21)
Bostan <i>et al</i> , 2022		43 y/o male, metastatic NET of unknown primary (atypical carcinoid likely)	Somatostatin analogs + CAPTEM (capecitabine 4500 mg/day for 14 days/temozolomide 360 mg/day for 5 days)	Treatment initiated after hypercortisolism control with 9 month follow up. A significant decrease was observed in the number, size, and metabolic activity uptake of metastatic foci.	(22)